COMMUNIQUÉS West-GlobeNewswire

Terns Pharmaceuticals Announces Leadership Changes

08/05/2024 - 22:05

FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

08/05/2024 - 22:05

Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling [...]

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

08/05/2024 - 22:05

Generated $24.7 million in net product sales of XDEMVY ® , an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and remain on-track [...]

RadNet Reports First Quarter Financial Results with Record First Quarter Revenue, Adjusted EBITDA(1) and Adjusted Earnings(3) and Revises Upwards 2024 Financial Guidance Ranges

08/05/2024 - 22:05

Total Company Revenue increased 10.5% to $431.7 million in the first quarter of 2024 from $390.6 million in the first quarter of 2023; Revenue from the Digital Health reportable segment increased 32.3% to $14.7 million [...]

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

08/05/2024 - 22:05

Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on track to initiate by [...]

NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update

08/05/2024 - 22:05

-- Revenue increased to $18.1 million in Q1 2024, a 25% increase over Q1 2023 -- -- Extended the maturity date of the Company’s term loan by one year to September 30, 2026 -- -- Maintained full-year 2024 revenue [...]

Surrozen Provides First Quarter 2024 Financial Results and Business Update

08/05/2024 - 22:05

SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan Preclinical data from ARVO 2024 demonstrate the promise of a Surrozen antibody based [...]

electroCore Announces First Quarter 2024 Financial Results

08/05/2024 - 22:05

Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023 Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST ROCKAWAY, N.J., May 08, 2024 (GLOBE [...]

Apollomics Announces Private Placement Financing and Addition to Board of Directors

08/05/2024 - 22:05

FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment- [...]

LifeMD Reports First Quarter 2024 Results; Raises Full Year Revenue Guidance

08/05/2024 - 22:05

First quarter revenue increased 33% year-over-year to $44.1 million with telehealth revenue growing 53% versus the year-ago period. Raising full-year revenue guidance to at least $205 million, up from prior guidance of [...]

RxSight, Inc. Announces Proposed Public Offering of Common Stock

08/05/2024 - 22:05

ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

08/05/2024 - 22:05

Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Ongoing ARDENT trial for SC291 continues in B-cell malignancies; expect [...]

Maravai LifeSciences Reports First Quarter 2024 Financial Results

08/05/2024 - 22:05

Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of [...]

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

08/05/2024 - 22:05

-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX- [...]

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

08/05/2024 - 22:05

Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial Data from Phase 3 PATHFNDR 1 and 2 [...]

Iridex to Report First Quarter 2024 Financial Results on May 14, 2024

08/05/2024 - 22:05

MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]

Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis

08/05/2024 - 22:05

Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON) Oculis also aims to complete an IND submission for OCS-05 in the U.S [...]

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024

08/05/2024 - 19:00

Conference Call Scheduled for Wednesday, May 15, 2024 at 9:00 AM ET PORTLAND, Maine, May 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company [...]

Q3 2023/24 - First sale of the XM30 completed

08/05/2024 - 18:20

ANNOUNCEMENT NO. 262 Trading statement for Q3 2023/24 (1 January - 31 March 2024) First sale of the XM30 completed Revenue declined by 6% in the third quarter of 2023/24 to DKK 98.9 million from DKK 105.4 million in the [...]